Patent · US Expired

Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy

US6361997B1 · kind B1 · utility

51Cited by
1References
2Claims
0Family size

Inventor

Key dates

Filing dateFeb 24, 2001
Grant dateMar 26, 2002
Priority date—
Expiry dateFeb 24, 2021

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to the use of genetically modified, very early haematopoietic and mesenchymal stem cells (negative for the expression of the surface molecule CD34) in the individual gene therapy of mono- or oligogenetic diseases or in cell therapy. Autologous CD34-negative adherently growing stem cell cultures from the peripheral blood of the patient are applied and efficiently tranfected or infected with genetic constructs. The gene products of these genes should substitute defective or absent proteins or factors in the patient organism in the long term. After expansion, the autologous stem cells can also be used for cell therapy (organ replacement therapy).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.